|
| 37400321 | Role of FDG PET/CT in Management of Patients with Prostate Cancer. | Semin Nucl Med | 2024 |
| 37591669 | The pen is mightier than the machine-artificial intelligence image generators in urology. | BJU Int | 2024 |
| 37891072 | Administering [<sup>177</sup>Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study. | Eur Urol | 2024 |
| 37696615 | Barriers and enablers of active surveillance for prostate cancer: a qualitive study of clinicians. | BJU Int | 2024 |
| 37691457 | How prostate-specific membrane antigen positron emission tomography is refining risk calculators in the primary prostate diagnostic pathway. | BJU Int | 2024 |
| 37973500 | Corrigendum to "Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis" [Eur. Urol. 84(1) (2023) 36-48]. | Eur Urol | 2024 |
| 37926642 | Awareness and Use of ChatGPT and Large Language Models: A Prospective Cross-sectional Global Survey in Urology. | Eur Urol | 2024 |
| 37423774 | The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature. | Eur Urol Oncol | 2024 |
| 36371669 | Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancer. | BJU Int | 2023 |
| 38017295 | Comparison of <sup>18</sup>F-based PSMA radiotracers with [<sup>68</sup>Ga]Ga-PSMA-11 in PET/CT imaging of prostate cancer-a systematic review and meta-analysis. | Prostate Cancer Prostatic Dis | 2023 |
| 38057191 | Cost Effectiveness of Systemic Treatment Intensification for Metastatic Hormone-sensitive Prostate Cancer: Is Triplet Therapy Cost Effective? | Eur Urol Oncol | 2023 |
| 37323189 | Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review. | Ther Adv Med Oncol | 2023 |
| 37182121 | US Food and Drug Administration Warning Regarding Finasteride and Suicidal Ideation: What Should Urologists Know? | Eur Urol Open Sci | 2023 |
| 37441340 | A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy. | Eur Urol Open Sci | 2023 |
| 37236856 | Re: Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence (NOSTONE). | Eur Urol | 2023 |
| 37303121 | Treatment de-intensification for low-risk biochemical recurrence after radical prostatectomy: rational or risky? | BJU Int | 2023 |
| 37168818 | NeoAdjuvant pembrolizumab and STEreotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): A phase II randomised clinical trial. | Contemp Clin Trials Commun | 2023 |
| 37101769 | A Systematic Review of the Variability in Performing and Reporting Intraprostatic Prostate-specific Membrane Antigen Positron Emission Tomography in Primary Staging Studies. | Eur Urol Open Sci | 2023 |
| 37099558 | Decade-long trends in prostate cancer biopsy grade groups and treatment within a population-based registry. | BJU Int | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 37099047 | Detecting localised prostate cancer using radiomic features in PSMA PET and multiparametric MRI for biologically targeted radiation therapy. | EJNMMI Res | 2023 |
| 37032189 | Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis. | Eur Urol | 2023 |
| 36404204 | Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer. | Eur Urol | 2023 |
| 36443163 | Modern Active Surveillance in Prostate Cancer: A Narrative Review. | Clin Genitourin Cancer | 2023 |
| 36473945 | Using PSMA imaging for prognostication in localized and advanced prostate cancer. | Nat Rev Urol | 2023 |
| 36910896 | Robotic-assisted radical prostatectomy: learning curves and outcomes from an Australian perspective. | Prostate Int | 2023 |
| 36509970 | Combination treatment in metastatic prostate cancer: is the bar too high or have we fallen short? | Nat Rev Urol | 2023 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 36411180 | Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: An updated systematic review and network meta-analysis. | Urol Oncol | 2023 |
| 36280500 | More Accurate Imaging Is Not Stage Migration: Time To Move from "Hubble" to "Webb" in Hormone-sensitive Prostate Cancer. | Eur Urol | 2023 |
| 34623735 | Self-reported lack of energy or feeling depressed 12Â months after treatment in men diagnosed with prostate cancer within a population-based registry. | Psychooncology | 2022 |
| 35440417 | Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. | Eur Urol | 2022 |
| 35504837 | Gender Disparities Among Editorial Boards of International Urology Journals. | Eur Urol Focus | 2022 |
| 35346516 | Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer. | Eur Urol | 2022 |
| 35764368 | Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes. | J Immunother Cancer | 2022 |
| 35697600 | EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [<sup>177</sup>Lu]Lu-PSMA Radioligand Therapy. | Eur Urol Oncol | 2022 |
| 35574991 | Prostate-specific membrane antigen positron emission tomography/computed tomography funding grants free access to superior staging for Australian men with prostate cancer. | BJU Int | 2022 |
| 35362659 | High prostate-specific membrane antigen (PSMA) positron emission tomography (PET) maximum standardized uptake value in men with PI-RADS score 4 or 5 confers a high probability of significant prostate cancer. | BJU Int | 2022 |
| 35750461 | Effects of a multicomponent resistance-based exercise program with protein, vitamin D and calcium supplementation on cognition in men with prostate cancer treated with ADT: secondary analysis of a 12-month randomised controlled trial. | BMJ Open | 2022 |
| 35450732 | Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. | Eur Urol | 2022 |
| 35681697 | PSMA PET-CT Imaging Predicts Treatment Progression in Men with Biochemically Recurrent Prostate Cancer-A Prospective Study of Men with 3 Year Follow Up. | Cancers (Basel) | 2022 |
| 36551620 | Distant Nodes Seen on PSMA PET-CT Staging Predicts Post-Treatment Progression in Men with Newly Diagnosed Prostate Cancer-A Prospective Cohort Study. | Cancers (Basel) | 2022 |
| 36536464 | Semi-quantitative and quantitative dynamic contrast-enhanced (DCE) MRI parameters as prostate cancer imaging biomarkers for biologically targeted radiation therapy. | Cancer Imaging | 2022 |
| 36075259 | Treatment options for metastatic hormone-sensitive prostate cancer. | Lancet Oncol | 2022 |
| 35868978 | Double or Triple Trouble in Metastatic Hormone-sensitive Prostate Cancer? | Eur Urol Oncol | 2022 |
| 36239736 | Systemic therapy in metastatic hormone-sensitive prostate cancer. | Curr Opin Support Palliat Care | 2022 |
| 36167774 | A decade of declining prostatectomy margin positivity within a prostate cancer clinical quality registry. | Urol Oncol | 2022 |
| 35892882 | Novel Germline Mutations in a Cohort of Men with Familial Prostate Cancer. | Cancers (Basel) | 2022 |
| 36225285 | Active surveillance versus nonradical treatment for low-risk men with prostate cancer: a review. | Prostate Int | 2022 |
| 35879832 | Active surveillance versus enzalutamide for low-risk prostate cancer - was it really a trial we needed? | BJU Int | 2022 |